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Abstract: In order to study methotrexate nephrotoxicity, the activities of proximal 
tubule epithelial cell membrane enzymes: alanine aminopeptidase (AAP) and gamma-
glutamyltransferase (GGT), as well as of lysosomal N-acetyl-beta-D-glucosaminidase 
(NAG) and urinary albumin concentrations were determined in 12-h-urine samples of 30 
patients with lymphoblastomous leukemia. The patients were i.v. receiving 4 individual me-
thotrexate doses of 2000 mg/m2 every 15 days followed by leucovorin as a protector. Con-
trol and methotrexate-treated group, each consisting of 30 examinees, included 4–10 years 
old children of both sexes. 
Statistically significant increase of AAP and GGT activities, expressed as U/mmol 
creatinine was observed after the first two (p < 0.05), as well as after the remaining two 
therapies (p < 0.01) in relation to the control. Enzymatic activities of these two enzymes 
decreased to control value before the second and the third methotrexate application, but 
they increased again after the third application and remained elevated up to the end of expe-
riments. Significant increase of NAG activity expressed as U/mmol creatinine  
(p < 0.01), as well as urinary albumin levels (mg/mmol creatinine; p < 0.01) were registered 
after the third methotrexate therapy and this elevation of the same statistical significance of 
the differences remained stable till the end of the therapy. Based on these results it can be 
concluded that during the time period of two first applications nephrotoxic methotrexate ac-
tion is reversible and at the level of proximal tubule epithelial cell membranes. During the 
last two applications impairment is irreversible and at the level of cell organelles and glo-
merular filtration. 
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Methotrexate, a known folate synthetase inhi-
bitor represents one of the first and most frequently 
used drugs in chemotherapy of malignancies. It has 
been applied as chemotherapeutic for almost five 
decades. It was shown to be efficient against numer-
ous malignancies such as leukemia, lymphoma, cho-
riocarcinoma, osteosarcoma and breast, head and 
lung tumors [1−5]. Methotrexate is usually applied 
by i.v. route in high, moderate and low doses [6]. 
High doses of 500 mg/m2 or even higher are used in 
the cases of leukemia, lymphoma, leptomeningeal 
metastases and osteosarcoma. Medium doses of 50 
to 500 mg methotrexate per m2 are given in cases of 
gestational trophoblastic diseases, while low doses  
(50 mg/m2 or lower) are applied during anti-
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inflammatory therapy of rheumatoid arthritis and 
psoriasis [7,8]. 
Intravenous methotrexate doses over 1.0 g/m2, 
frequently result in a series of systemic toxicities. 
Besides the skin, mucous membranes, liver and 
brain, they also affect the kidneys [9]. Methotrexate 
can exert toxic effects on glomerular and tubular 
functioning, but some clinical studies showed that it 
is not a general phenomenon [10]. Even low and 
moderate intravenously applied methotrexate doses 
aggravate the existing glomerular and tubular cell 
necrosis. The risk of nephrotoxic methotrexate ac-
tion can be elevated by genetic polymorphism in-
cluded in folate metabolism [11]. 
In the studies published so far, determination 
of methotrexate nephrotoxicity was performed dur-
ing the application of low doses of the drug in the 
cases of anti-inflammatory treatment of rheumatoid 
arthritis and psoriasis. In earlier reports, glomerular 
function was checked by measuring clearance of 
inulin, creatinine and ethylenediaminetetraacetate 
(EDTA), as well as by increased albumin concentra-
tion in urine [12]. Tubular function was estimated by 
determining the blood concentration of electrolytes, 
content of alfa-1- or beta-2-microglobulins in urine 
and by tubular enzymuria [13,14]. 
The present study aimed at determining possi-
ble nephrotoxic methotrexate effects in the repre-
sentative number of patients suffering from acute 
lymphoblastomous leukemia treated with high doses 
of the drug. Glomerular toxicity was estimated via 
the determination of albuminuria, and tubular toxici-
ty by determining enzyme activities of AAP (EC 3. 
4. 11. 2), GGT (EC 2. 3. 2. 2), and NAG (EC 3. 2. 1. 
52), known as very sensitive markers of epithelial 
proximal tubule cell damages.  
 
 
2. EXPERIMENTAL SECTION 
 
Sixty children aged between 4 and 10 years, 
all of them patients of the Pediatric Hospital of the 
University Clinical Center, Banjaluka were included 
in the present study. The experimental group con-
sisted of 30 patients with diagnosed lymphoblas-
tomous leukemia receiving i.v. four intramittent me-
thotrexate doses of 2000 mg/m2 every 15 days, each 
of them followed by protective leucovorin doses of 
15 mg/m2, 42, 48 and 54 h after methotrexate. The 
control group included 30 examinees without either 
lymphoblastomous leukemia or some other kidney- 
or urinary tract-connected disorders and without me-
thotrexate application.  
Twelve-h-urine samples in triplicates, col-
lected in the morning 24 h before and 24 h after each 
methotrexate treatment were kept at −25 oC till the 
analysis. The data on age, sex, body height and 
mass, and the health status of the patients were in-
troduced into a questionnaire during the first urine 
collection. 
Before urine analysis, the enzymes were sepa-
rated by gel filtration [15]. Enzymatic activities of 
AAP [16], GGT [17] and NAG [18,19] expressed as 
U/mmol creatinine [20], and concentrations of uri-
nary albumin [21,22] expressed as mg/mmol creati-
nine, were determined by spectrophotometry.  
The results analyzed by standard statistical 
methods are presented graphically and in tables as 
mean values ± standard deviation. Thesignificance 
of differences between the experimental group and 
the control was estimated by Student t-test. 
 
 
3. RESULTS   
 
Enzymatic AAP, GGT and NAG activities, as 
well as urinary concentrations of albumin presented 
as mean values ± S.D. are described in Table 1-4. As 
seen in Table 1, a statistically significant increase of 
AAP activity in urine samples of patients treated 
with methotrexate in relation to the control was rec-
orded after each of four therapies. 
 
Table 1. Average values (± SD) of the activities AAP in urine of children treated with four therapeutic doses of metho-
trexate in relation to the corresponding controls 
methotrexate   
   therapies 
control 
group, values in units 
experimental 
group, values in units 
p 
I 0.37 ± 0.12 0.47 ± 0.17 p < 0.05 
II 0.38 ± 0.11 0.54 ± 0.19 p < 0.05 
III 0.35 ± 0.10 0.60 ± 0.20 p < 0.01 
IV 0.37 ± 0.12 0.69 ± 0.23 p < 0.01 
 
 
Similarly to AAT, the mean values of enzy-
matic GGT activity were significantly increased af-
ter the first, after the second, after the third and after 
the fourth therapy in experimental group in relation 
to the control (Table 2)  
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Twenty-four hours before the onset of the 
second and third methotrexate treatment the activi-
ties of AAP and GGT were decreased to control val-
ue. However, the activities of these enzymes after 
the third, as well as before the fourth methotrexate 
treatment remained significantly elevated up to the 
last experimental point, i. e. 24 h after the last appli-
cation of the drug. 
 
Table 2. Average values (± SD) of the activities GGT in urine of children treated with four therapeutic doses of metho-
trexate in relation to the corresponding controls 
methotrexate   
   therapies 
control 
group, values in units 
experimental 
group, values in units 
p 
I 3.84 ± 1.12 4.85 ± 1.61 p < 0.05 
II 3.62 ± 1.20 5.45 ± 1.84 p < 0.05 
III 3.45 ± 1.15 5.72 ± 1.92 p < 0.01 
IV 3.51 ± 1.17 5.57 + 1.85 p < 0.01 
 
 
Changes in NAG activity during the experi-
mental period are described in Table 3. As shown, a 
statistically significant increase of this enzyme activ-
ity in methotrexate-treated group of patients in com-
parison with the control was observed after the third 
treatment to remain significantly elevated up to the 
end of the therapy. 
An increased albumin level in the form of mi-
croalbuminuria was recorded after the third treat-
ment with methotrexate and the same level of statis-
tical significance of the differences was recorded till 
the end of the therapy (Table 4) 
 
Table 3. Average values (± SD) of the activities NAG in urine of children treated with four therapeutic doses of metho-
trexate in relation to the corresponding controls 
methotrexate   
   therapies 
control 
group, value in units 
experimental 
group, value in units 
p 
I 0.27 ± 0.09 0.29 ± 0.08 p > 0.05 
II 0.31 ± 0.11 0.32 ± 0.10 p > 0.05 
III 0.29 ± 0.09  0.46 ± 0.15 p < 0.01 
IV 0.28 ± 0.07  0.59 ± 0.19 p < 0.01 
 
Table 4. Average values (± SD) of the concentrations albumine in urine of children treated with four therapeutic doses 
of methotrexate in relation to the corresponding controls 
methotrexate   






I 1.99 ± 0.66 2.20 ± 0.71 p > 0.05 
II 1.98 ± 0.68 1.96 + 0.68 p > 0.05 
III 2.33 ± 0.77 5.30 ± 1.81 p < 0.01 
IV 2.28 ± 1.0 7.11 ± 2.83 p < 0.01 
 
 
4. DISCUSSION  
     
In the present work, nephrotoxic effects of i.v. 
methotrexate therapy were studied in the group of 
children suffering from lymphoblastomous leuke-
mia, aged between 4 and 10 years of both sexes. The 
increased enzymatic activities of AAP and GGT 
(enzymes of the proximal tubule epithelial cell 
membranes) in urine pointed to methotrexate-
induced injuries of this kidney tissue. At the same 
time, harmful effects of methotrexate application 
were seen as a significantly increased activity of ly-
sosomal enzyme NAG. In addition, significantly 
elevated albumin levels in urine of the patients dem-
onstrated disturbances in glomerular filtration. 
Enzymatic AAP and GGT activities were sig-
nificantly increased already after the first methotrex-
ate application, but a 15-day-period between the first 
and the second therapy was sufficient for recupera-
tion of kidney cells, seen as decreased activities of 
these two enzymes to the control levels. A similar 
trend was also observed after the second methotrex-
ate treatment, i. e. after an initial increase in AAP 
and GGT activities registered 24 h upon the therapy, 
the activities of these two enzymes declined to con-
trol values before the third methotrexate application. 
These results are in accordance with our previous 
findings demonstrating that AAP and GGT represent 
early, reliable and very sensitive markers of reversi-
ble changes in epithelial cell membranes of proximal 
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tubules [23]. The activities of AAP and GGT  also 
significantly increased upon the third methotrexate 
treatment to remain elevated till the end of the expe-
rimental period. These results ainindubitably pointed 
to severe and irreversible methotrexate-induced inju-
ries of proximal tubule epithelial cells. After the first 
two methotrexate treatments of the patients, no sig-
nificant changes in NAG activity were observed. 
However, the activity of this enzyme was signifi-
cantly increased after both the third and the fourth 
methotrexate application, clearly demonstrating se-
rious and irreversible damages in proximal tubule 
epithelial cells at the level of cell organelles. These 
results are in agreement with the report of Wilanda 
et al. [24], although they do not support the findings 
of Hempel et al. [9]. 
After the third methotrexate therapy, albumin 
concentration in urine was significantly increased 
pointing to methotrexate-induced damages of glome-
rules. These changes at the level of microalbuminu-
ria persisting up to the end of the experiment are 
partially in accordance with earlier findings of Vujić 






Based on the results obtained throughout the 
present study, it can be concluded that high metho-
trexate doses given to children with acute lymphob-
lastomous leukemia exert severe nephrotoxic effects. 
After the first two methotrexate therapies these ef-
fects are expressed as reversible changes in epitheli-
al proximal tubule cells. However, the next two 
therapies lead to irreversible changes accompanied 
by an impairment at the level of kidney cell orga-
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АКТИВНОСТИ ЕНЗИМА ПРОКСИМАЛНИХ ТУБУЛА И КОНЦЕНТРАЦИЈА  
АЛБУМИНА У УРИНУ ДЈЕЦЕ ТРЕТИРАНЕ МЕТОТРЕКСАТОМ 
 
Сажетак: Ради утврђивања нефротоксичности метотрексата, одређивани су 
ензимска активност ензима мембрана ћелија епитела проксималних тубула, 
аланинаминопептидазе (ААП) и гама-глутамилтрансферазе (ГГТ), лизозомалног ензима 
Н-ацетил-бета-Д-глукозаминидазе (НАГ) и концентрација албумина у урину. Одређивања 
су вршена у узорцима 12-часовог урина код 30 испитаника који су били обољели од 
лимфобластне леукемије. Њима је метотрексат аплициран интравенски у четири 
појединачне дозе од 2000 mg/m2 са размаком  од 15 дана и уз заштиту са леуковорином. 
Иста одређивања су вршена и у 12-часовном урину 30 испитаника контролне групе. Обје 
групе су се састојале од испитаника оба пола, старости од 4 до 10 година. 
Статистички значајно повећање активности ААП и ГГТ, изражених у U/mmol 
кретинина, експерименталне у односу на контролну групу је регистровано након прве 
двије терапије (p < 0,05) и након друге двије терапије (p < 0,01). Активности ова два 
ензима експерименталне групе нормализовале су се до почетка друге, односно треће 
апликације метотрексата, али су се опет повећеле након треће апликације и остале 
увећане све до краја експеримента. Сигнификантни порасти активности НАГ у U/mmol 
креатинина (p < 0,01) и концентрације албумина у mg/mmol креатинина (p < 0,01) су 
регистровани након треће терапије и повећања са истом статистичком значајношћу су 
задржана све до краја терапије. На основу добијених резултата може се закључити да је, 
за вријеме двије прве примјене лијека, нефротоксично дјеловање метотрексата 
Tatjana Vujić, et al., Activities of proximal tubule enzymes and albumin concentration in urine… 
Contemporary Materials, VI−1 (2015)                                                                                                             Page 79 of 79 
 
реверзибилно и на нивоу ћелија мембрана епитела проксималних тубула. За вријеме двије 
посљедње примјене лијека оштећења су иреверзибилна и на нивоу ћелијских органела и 
гломеруларне филтрације.   
Кључне ријечи: аланинаминопептидаза (ААП), гама-глутамилтрансфераза (ГГТ), 
Н-ацетил-бета-Д-глукозаминидаза (НАГ), албумин, урин, метотрексат. 
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